市場調査レポート

世界の経鼻薬剤投与市場とパイプラインの分析

Global Intranasal Drug Delivery Market & Pipeline Insight

発行 KuicK Research 商品コード 311720
出版日 ページ情報 英文 566 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
世界の経鼻薬剤投与市場とパイプラインの分析 Global Intranasal Drug Delivery Market & Pipeline Insight
出版日: 2014年09月01日 ページ情報: 英文 566 Pages
概要

スプレーや吸入器などによる薬剤の自己投与を選ぶ患者が増えるなか、これらの経鼻的薬剤投与製品の市場は近い将来において確実に成長する見通しです。また、この需要の拡大は、新たな企業による参入を大いに刺激するものとなるでしょう。慢性的疾患の発症件数も今後は増加する見通しであり、これらの事情も経鼻薬剤投与技術の市場を推進する主要な要因となるでしょう。

当レポートでは、経鼻薬剤投与の市場について調査し、経鼻薬剤投与のメカニズムと投与形態、目的、市場規模の推移と予測、適応症・フェーズ・企業・国別のパイプライン薬のプロファイル、上市済み薬剤のプロファイル、主要製薬会社の取り組みなどをまとめています。

第1章 イントロダクション:経鼻薬剤投与

第2章 経鼻薬剤投与のメカニズム

  • 経鼻吸収のメカニズム
  • 経鼻用薬剤のタイプ
    • 液体製剤
    • 加圧MDI
    • 粉末用デバイス
    • 経鼻用ゲル

第3章 経鼻薬剤投与のニーズ

第4章 経鼻薬剤投与の用途

  • 非ペプチド医薬品の投与
  • ペプチド医薬品の投与
  • 経鼻腔による脳へのドラッグデリバリー
  • 経鼻腔によるワクチンのデリバリー
  • 診断薬のデリバリー

第5章 経鼻薬剤投与市場の概要

  • 現在の市場シナリオ
  • 経鼻薬剤のパイプラインの概要

第6章 市場力学

  • 好ましい市場のパラメーター
  • ドラッグデリバリーにおける課題

第7章 将来の展望

  • 将来のシナリオ
  • デリバリーデバイスの進化

第8章 経鼻薬剤の臨床パイプラン:適応症・フェーズ・企業・国別

  • 研究
  • 前臨床
  • 臨床
  • フェーズI
  • フェーズI/II
  • フェーズII
  • フェーズII/III
  • フェーズIII
  • 登録前
  • 登録済み

第9章 上市済み経鼻薬剤:適応症・企業・国別

第10章 開発延期・中止の薬剤:適応症・フェーズ・企業・国別

  • 進捗報告なし
  • 中止
  • 市場撤退
  • 延期

第11章 競合環境

  • Aegis Therapeutics
  • Archimedes Pharma
  • GlaxoSmithKline
  • MEDA AB
  • MedImmune
  • Merck
  • NanoBio Corporation
  • Novartis
  • OptiNose
  • Pherin Pharmaceuticals

図表

目次

Intranasal drug delivery has evolved in the recent years as a significant method of delivering drugs through the nasal route. This method has been identified to have all the potential to achieve significant milestones in the pharmaceutical industry, as it is largely driven by its capability to cure local infections and chronic allergies. The human nose, which has a unique vascular structure, makes it specifically accessible for delivering small molecule drugs and biologics. By taking advantage of the conducive healthcare trends and changing demography, the intranasal drug delivery route is likely to capture the popularity of other leading methods of drug delivery such as oral and parenteral.

The use of nasal sprays and inhalers has had a great impact in improving the drug administration experience, enhancing compliance rates, and ensuring safety. These systems have emerged as a segment with huge potential for the future and are playing an increasingly prominent role in a range of competitive intranasal devices markets. The growth and competitiveness of the intranasal drugs and devices market has led to the extensive development and innovation of new and nth-generation devices which have the capacity to overcome the limitations of the previous drug delivery technologies.

With an increasing number of patients preferring to use self-administering devices like sprays and inhalers to avoid the pain, the market for these products is likely to grow at a substantial rate in the near future. This increasing demand is also having a great impact in terms of attracting new companies into the market. The future years are expected to witness a steady increase in chronic diseases, if not a rapid increase and this is also a major driver of intranasal drug delivery technologies.

The intranasal drug delivery market is likely to witness more developments in formulation techniques, like improvised micro-encapsulation techniques, more use of muco adhesive and surfactant agents and nanotechnology. This would in turn lead to an increased number of new chemical entities which could possibly be considered as the active ingredients for future intranasal drug products. Similarly, it is also expected that modern approaches to vaccination would be increasingly used which could also generate a wide range of new prophylactic and therapeutic products which would be appropriate for delivery through the nasal route.

“Global Intranasal Drug Delivery Market & Pipeline Insight” Report Highlights:

  • Intranasal Drug Delivery Market Overview
  • Mechanism & Application Intranasal Drug Delivery
  • Nasal Drug Delivery System: Powder, Gels, Liquid & Pressurized MDI
  • Intranasal Drug Clinical Pipeline Insight by Indication, Phase, Company & Country
  • Intranasal Drug Clinical Pipeline: 177 Drugs
  • Majority Drugs in Preclinical Phase: 65
  • Market Intranasal Drugs: 34

Table of Contents

1. Introduction to Intranasal Drug Delivery

2. Intranasal Drug Delivery Mechanism

  • 2.1. Mechanism of Nasal Absorption
  • 2.2. Types of Nasal Drug Delivery System Dosages
    • 2.2.1. Liquid Nasal Formulations
    • 2.2.2. Pressurized MDI
    • 2.2.3. Powder Devices
    • 2.2.4. Nasal Gels

3. Need for Intranasal Drug Delivery

4. Applications of Intranasal Drug Delivery

  • 4.1. Delivery of Non Peptide Pharmaceuticals
  • 4.2. Delivery of Peptide Based Pharmaceuticals
  • 4.3. Delivery of Drugs to Brain through Nasal Cavity
  • 4.4. Delivery of Vaccines through Nasal Route
  • 4.5. Delivery of Diagnostic Drugs

5. Intranasal Drug Delivery Market Overview

  • 5.1. Current Market Scenario
  • 5.2. Intranasal Drug Clinical Pipeline Overview

6. Intranasal Drug Delivery Market Dynamics

  • 6.1. Favorable Market Parameters
  • 6.2. Challenges in Drug Delivery

7. Intranasal Drug Delivery Market Future Outlook

  • 7.1. Future Scenario
  • 7.2. Advances in Delivery Devices

8. Intranasal Drug Clinical Pipeline by Indication, Phase, Company & Country

  • 8.1. Research
  • 8.2. Preclinical
  • 8.3. Clinical
  • 8.4. Phase-I
  • 8.5. Phase-I/II
  • 8.6. Phase-II
  • 8.7. Phase-II/III
  • 8.8. Phase-III
  • 8.9. Preregistration
  • 8.10. Registered

9. Marketed Intranasal Drugs by Indication, Company & Country

10. Suspended & Discontinued Intranasal Drugs in Clinical Pipeline by Indication, Phase, Company & Country

  • 10.1. No Development Reported
  • 10.2. Discontinued
  • 10.3. Market Withdrawal
  • 10.4. Suspended

11. Competitive Landscape

  • 11.1. Aegis Therapeutics
  • 11.2. Archimedes Pharma
  • 11.3. GlaxoSmithKline
  • 11.4. MEDA AB
  • 11.5. MedImmune
  • 11.6. Merck
  • 11.7. NanoBio Corporation
  • 11.8. Novartis
  • 11.9. OptiNose
  • 11.10. Pherin Pharmaceuticals

List of Figures

  • Figure 1-1: Intranasal Drug Delivery Formulations
  • Figure 2-1: Intranasal Drug Delivery Mechanism
  • Figure 2-2: Nasal Drug Delivery System Dosages Forms
  • Figure 5-1: Composition of Drug Delivery Market
  • Figure 5-2: Global Intranasal Drug Delivery Market (US$ Billion), 2013-2018
  • Figure 5-3: Intranasal Drug Delivery Therapeutic Applications
  • Figure 5-4: Regional Break-up of Intranasal Drug Delivery Market
  • Figure 5-5: Intranasal Drug Clinical Pipeline by Phase (%), 2014
  • Figure 5-6: Intranasal Drug Clinical Pipeline by Phase (Number), 2014
  • Figure 5-7: No Development Reported in Intranasal Drug by Phase (%), 2014
  • Figure 5-8: No Development Reported in Intranasal Drug by Phase (Number), 2014
  • Figure 5-9: Discontinued Intranasal Drug in Pipeline by Phase (%), 2014
  • Figure 5-10: Discontinued Intranasal Drug in Pipeline by Phase (Number), 2014
  • Figure 5-11: Suspended Intranasal Drug in Pipeline by Phase (%), 2014
  • Figure 5-12: Suspended Intranasal Drug in Pipeline by Phase (Number), 2014
  • Figure 11-1: NanoBio Clinical Pipeline
  • Figure 11-2: Pherin Pharmaceuticals
Back to Top